Innovation and strategic divergence: An empirical study of the U.S. pharmaceutical industry from 1920 to 1960

Management Science

Volumn 49, Issue 2, 2003, Pages 143-159

  Lee, Jeho ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Innovation; Schumpeterian competition; Strategies groups

Indexed keywords

DRUG PRODUCTS; INVESTMENTS; PRODUCT DEVELOPMENT; RESEARCH AND DEVELOPMENT MANAGEMENT;

INNOVATION; PHARMACEUTICAL INDUSTRY; STRATEGIC DIVERGENCE;

INDUSTRIAL MANAGEMENT;

EID: 0037299889     PISSN: 00251909     EISSN: None     Source Type: Journal    
DOI: 10.1287/mnsc.49.2.143.12745     Document Type: Article

References (55)

1. Amel, D. F., S. Rhoades. 1988. Strategic groups in banking. Rev. Econom. Statist. 70 685-689.
2. Arthur D. Little, Inc. 1962. A Report on the Aspects of Concentration and Product Obsolescence in the Pharmaceutical Industry in the United States. Acorn Park, Cambridge, MA.
3. Athey, S., A. Schmutzler. 2001. Investment and market dominance. RAND J. Econom. 32 1-26.
4. Bagwell, K., G. Ramey. 1994. Coordination economies, advertising, and search behavior in retail markets. Amer. Econom. Rev. 84 498-517.
5. Barney, J. B., R. E. Hoskisson. 1990. Strategic groups: Untested assertions and research proposals. Management Decision Econom. 11 187-198.
6. Burlingham, R. 1951. The Odyssey of Modern Drug Research. Upjohn Company, Kalamazoo, MI.
7. Caves, R. E. 1984. Economic analysis and the quest for competitive advantage. Amer. Econom. Rev. 74 127-132.
8. ____, M. E. Porter. 1977. From entry barriers to mobility barriers. Quart. J. Econom. 91 241-261.
9. Cohen, W., D. Levinthal. 1989. Innovation and learning: The two faces of R&D. Econom. J. 99 569-596.
10. ____, ____. 1994. Fortune favors the prepared firm. Management Sci. 40 227-251.
11. Comanor, W. S. 1963. The economics of research and development in the pharmaceutical industry. Unpublished doctoral dissertation, Harvard University, Cambridge, MA.
12. Cool, K. O. 1985. Strategic group formation and strategic group shifts: A longitudinal analysis of the U.S. pharmaceutical industry, 1963-1982. Unpublished doctoral dissertation, Purdue University, West Lafayette, IN.
13. ____, D. Schendel. 1987. Strategic group formation and performance: U.S. pharmaceutical industry 1963-1982. Management Sci. 33 1102-1124.
14. ____, ____. 1988. Performance differences among strategic group members. Strategic Management J. 9 207-223.
15. De Haen, P. 1962. Review of drugs, 1941-1961: Single chemical entities introduced in the United States and patent status. Unpublished report, Pharmaceutical Manufacturers Association, Washington, D.C.
16. Dranove, D., M. Peteraf, M. Shanley. 1998. Do strategic groups exist?: An economic framework for analysis. Strategic Management J. 19 1029-1044.
17. Federal Trade Commision. 1958. Economic report on antibiotics manufacture. United States Government Printing Office, Washington, D.C.
18. Gambardella, A. 1992. Competitive advantages from in-house scientific research: The U.S. pharmaceutical industry in the 1980s. Res. Policy 21 391-407.
19. Grabowski, H. G. 1976. Drug Regulation and Innovation: Empirical Evidence and Policy Options. American Enterprise Institute for Public Policy Research, Washington, D.C.
20. Hamilton, L. C. 1992. Regression with Graphics: A Second Course in Applied Statistics. Brooks-Cole, Belmont, CA.
21. Hausman, J., B. H. Hall, Z. Griliches. 1984. Econometric models for count data with an application to the patents-R&D relationship. Econometrica 52 909-938.
22. Henderson, R., I. Cockburn. 1996. Scale, scope, and spillovers: The determinants of research productivity in drug discovery. RAND J. Econom. 27 32-59.
23. Kurdas, C. 1998. Dynamic economies of scope in the pharmaceutical industry. Indust. Corporate Change 7 501-521.
24. Layman, P. L. 1988. Global pharmaceutical industry undergoing major shifts. Chemical Engrg. News 29 August 16.
25. Lee, J. 1996. Change agents and the evolution of the U.S. pharmaceutical industry, 1920-1960. Unpublished doctoral dissertation, University of Pennsylvania, Philadelphia, PA.
26. ____, K. Lee, S. Rho. 2002 An evolutionary perspective on strategic group emergence: A genetic algorithm-based model. Strategic Management J. 23 727-746.
27. Liebenau, J. 1985. Innovation in pharmaceuticals: Industrial R&D in the early twentieth century. Res. Policy 14 179-187.
28. ____, 1987. Medical Science and Medical Industry: The Formation of the American Pharmaceutical Industry. Johns Hopkins University Press, Baltimore, MD.
29. Mahoney, T. 1959. The Merchants of Life: An Account of the American Pharmaceutical Industry. Harper & Brothers Publishers, New York.
30. Mascarenhas, B. 1989. Strategic group dynamics. Acad. Management J. 32 333-352.
31. McGee, J., H. Thomas, M. Pruett. 1995. Strategic groups and the analysis of market structure and industry dynamics. British J. Management 6 257-270.
32. National Research Council. 1920, 1921. Research Laboratories in Industrial Establishments of the United States. Washington, D.C.
33. ____, 1927, 1931, 1933, 1938, 1940, 1946, 1950, 1956, 1960. Industrial Research Laboratories of the United States. Washington, D.C.
34. Nelson, R. R., S. G. Winter. 1978. Force generating and limiting concentration under Schumpeterian competition. Bell J. Econom. 9 524-548.
35. ____, ____. 1982. An Evolutionary Theory of Economic Change. Belknap Press of Harvard University Press, Cambridge, MA.
36. Peteraf, M., D. Shanley. 1997. Getting to know you: A theory of strategic group identity. Strategic Management J. 18 519-528.
37. Porter, M. E. 1979. The structure within industries and company performance. Rev. Econom. Statist. 61 214-227.
38. ____. 1980. Competitive Strategy. Free Press, New York.
39. Raper, K. B. 1952. A decade of antibiotics in America. Mycologia 44 1-59.
40. Rumelt, R. P., D. Schendel, D. Teece. 1994, Fundamental issues in strategy. R. P. Rumelt, D. Schendel, D. Teece, eds. Fundamental Issues in Strategy. Harvard Business School Press, Cambridge, MA, 9-53.
41. Schmalensee, R. 1985. Do markets differ much? Amer. Econom. Rev. 75 341-351
42. Schwartzman, D. 1976. Innovation in the Pharmaceutical Industry. Johns Hopkins University Press, Baltimore, MD.
43. Schwertman, N. C., L. K. Heilbrun. 1986. A successive differences method for growth curves with missing data and random observation times. J. Amer. Statist. Assoc. 81 912-916.
44. Shipman, P. 1981. Life History of A Fossil: An Introduction to Taphonomy and Paleoecology. Harvard University Press, Cambridge
45. Spilker, B. 1989. Multinational Drug Companies: Issues in Drug Discovery and Development. Raven Press, New York.
46. Statman, M. 1983. Competition in the Pharmaceutical Industry: The Declining Profitability of Drug Innovation. American Enterprise Institute for Public Policy Research, Washington, D.C.
47. Stock, F. J. 1943. Amer. Pharmaceutical Manufacturers Assoc. Proc. Midyear meeting, December, 194.
48. ____. 1945. Penicillin production and distribution. J. Amer. Pharmaceutical Association, Practical Pharmacy Edition 6(April) 110-114.
49. Sutton, J. 1991. Sunk Costs and Market Structure: Price Competition, Advertising, and the Evolution of Concentration. MIT Press, Cambridge, MA.
50. Temin, P. 1980. Taking Your Medicine: Drug Regulation in the United States. Harvard University Press, Cambridge, MA.
51. U.S. Congress, Senate. 1961. Administered prices: Drugs. Senate Report 449, 87th Congress, 1st Session, Washington, D.C.
52. U.S. Congress, Office of Technology Assessment. 1993. Pharmaceutical R&D: Costs, Risks and Rewards, OTA-H-522. U.S. Government Printing Office, Washington, D.C.
53. Wainwright, M. 1990. Miracle Cure: The Story of Penicillin and the Golden Age of Antibiotics. Basil Blackwell, Cambridge, MA.
54. Wiggins, R. R., T. W. Ruefli. 1995. Necessary conditions for the predictive validity of strategic groups: Analysis without reliance on clustering techniques. Acad. Management J. 33 1635-1656.
55. Wilkinson, H. S. 1959. History and evolution of the pharmaceutical industry. J. Amer. Pharmaceutical Indust. 20 592.